

## DAFTAR PUSTAKA

1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. *Journal of Autoimmunity* [Internet]. 2020;109(February):102433. Available from: <https://doi.org/10.1016/j.jaut.2020.102433>
2. Chugh T. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information. *Current Medicine Research and Practice*. 2020;10(January):137–8.
3. Calina D, Docea AO, Petrakis D, Egorov AM, Ishmukhametov AA, Gabibov AG, et al. Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review). Vol. 46, *International journal of molecular medicine*. 2020. p. 3–16.
4. Krammer F. SARS-CoV-2 vaccines in development. *Nature* [Internet]. 2020;586(7830):516–27. Available from: <http://dx.doi.org/10.1038/s41586-020-2798-3>
5. World Health Organization. VACCINE SAFETY BASICS Learning manual. World Health Organization [Internet]. 2013;207. Available from: [http://www.who.int/vaccine\\_safety/initiative/tech\\_support/Vaccine-safety-E-course-manual.pdf?ua=1](http://www.who.int/vaccine_safety/initiative/tech_support/Vaccine-safety-E-course-manual.pdf?ua=1)
6. Ophinni Y, Hasibuan AS, Widhani A, Maria S, Koesnoe S, Yuniastuti E, et al. COVID-19 Vaccines: Current Status and Implication for Use in Indonesia. *Acta Med Indones*. 2020;52(4):388–412.
7. Ouassou H, Kharchoufa L, Bouhrim M, Daoudi NE, Imtara H, Bencheikh N, et al. The Pathogenesis of Coronavirus Disease 2019 (COVID-19): Evaluation and Prevention. Vol. 2020, *Journal of Immunology Research*. Hindawi Limited; 2020.
8. Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease 2019 (COVID-19): A literature review. Vol. 13, *Journal of Infection and Public Health*. Elsevier Ltd; 2020. p. 667–73.
9. Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, et al. The epidemiology and clinical information about COVID-19. Vol. 39, *European Journal of Clinical Microbiology and Infectious Diseases*. Springer; 2020. p. 1011–9.
10. Hikmawati I, Setiyabudi R. Epidemiology of COVID-19 in Indonesia: common source and propagated source as a cause for outbreaks. *Journal of Infection in Developing Countries*. 2021 May 1;15(5):646–52.
11. Baj J, Karakuła-Juchnowicz H, Teresiński G, Buszewicz G, Ciesielka M, Sitarz E, et al. COVID-19: Specific and non-specific clinical manifestations and symptoms: The current state of knowledge. Vol. 9, *Journal of Clinical Medicine*. MDPI; 2020. p. 1–22.
12. Kordzadeh-Kermani E, Khalili H, Karimzadeh I. Pathogenesis, clinical manifestations and complications of coronavirus disease 2019 (COVID-19). Vol. 15, *Future Microbiology*. Future Medicine Ltd.; 2020. p. 1287–305.

13. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Vol. 109, *Journal of Autoimmunity*. Academic Press; 2020.
14. Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Vol. 55, *European Respiratory Journal*. European Respiratory Society; 2020.
15. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Vol. 215, *Clinical Immunology*. Academic Press Inc.; 2020.
16. Bergmann CC, Silverman RH. COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies. *Cleveland Clinic Journal of Medicine*. 2020;87(5):321–7.
17. Chowdhury MA, Hossain N, Kashem MA, Shahid MA, Alam A. Immune response in COVID-19: A review. Vol. 13, *Journal of Infection and Public Health*. Elsevier Ltd; 2020. p. 1619–29.
18. Adijaya O, Perwira Bakti A. Peningkatan Sistem Imunitas Tubuh Dalam Menghadapi Pandemi Covid-19.
19. Sugitha KSL. COVID-19: Respon imunologis, ketahanan pada permukaan benda dan pilihan terapi klinis. *Intisari Sains Medis*. 2020 Aug 1;11(2):791.
20. Rosyanti L, Hadi I, Keperawatan Poltekkes Kemenkes Kendari J. RESPON IMUNITAS DAN BADAI SITOKIN SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 LITERATUR REVIEW The Immunity Response and Severe Acute Respiratory Syndrome Coronavirus-2 Cytokine Storm Literature Review. *Jurnal Kesehatan Madani Medika [Internet]*. 11(02):176–201. Available from: <https://covid19.go.id/>
21. Mortaz E, Tabarsi P, Varahram M, Folkerts G, Adcock IM. The Immune Response and Immunopathology of COVID-19. Vol. 11, *Frontiers in Immunology*. Frontiers Media S.A.; 2020.
22. Delang L, Neyts J. Medical treatment options for COVID-19. *European Heart Journal: Acute Cardiovascular Care*. 2020 Apr;9(3):209–14.
23. Instiaty, Sri Darmayani IGAAP, Marzuki JE, Angelia F, William, Siane A, et al. Antiviral treatment of covid-19: A clinical pharmacology narrative review. Vol. 29, *Medical Journal of Indonesia*. Faculty of Medicine, Universitas Indonesia; 2020. p. 332–45.
24. Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: The reality and challenges. Vol. 53, *Journal of Microbiology, Immunology and Infection*. Elsevier Ltd; 2020. p. 436–43.
25. Pelletier JPR, Mukhtar F. Passive Monoclonal and Polyclonal Antibody Therapies. In: *Immunologic Concepts in Transfusion Medicine*. Elsevier; 2020. p. 251–348.
26. Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: The reality and challenges. Vol. 53, *Journal of Microbiology, Immunology and Infection*. Elsevier Ltd; 2020. p. 436–43.
27. Hartanti D, Dhiani A, Lintang Charisma S, Wahyuningrum R. ARTICLE HISTORY The Potential Roles of Jamu for COVID-19: A Learn from the Traditional Chinese Medicine.

Pharmaceutical Sciences and Research (PSR) [Internet]. 7:12–22. Available from: <http://www.theplantlist.org/>

28. Aeni N, Perencanaan B, Daerah P, Pati K, Raya J, Km PK, et al. Pandemi COVID-19: Dampak Kesehatan, Ekonomi, dan Sosial COVID-19 Pandemic: The Health, Economic, and Social Effects [Internet]. Vol. 17. 2021. Available from: <http://>
29. Nasution DAD, Erlina E, Muda I. Dampak Pandemi COVID-19 terhadap Perekonomian Indonesia. *Jurnal Benefita*. 2020 Jul 31;5(2):212.
30. Siahaan M, Akuntansi P, Ekonomi F, Bhayangkara U, Raya J, Raya Perjuangan J, et al. Halaman: 1-3 Terakreditasi Peringkat 5 (SINTA 5) sesuai SK RISTEKDIKTI Nomor [Internet]. Edisi Khusus. 2020. Available from: <http://ejournal.ubharajaya.ac.id/index.php/JKI>
31. Wahyu Pratama Putra dan Kurnia Sari Kasmiarno M, Wahyu Pratama Putra M, Sari Kasmiarno K, Magister Agama dan Lintas Budaya Minat Ekonomi Islam M. PENGARUH COVID-19 TERHADAP KEHIDUPAN MASYARAKAT INDONESIA: SEKTOR PENDIDIKAN, EKONOMI DAN SPIRITUAL KEAGAMAAN [Internet]. Vol. 1, POROS ONIM. 2020. Available from: <http://e-journal.iainfmpapua.ac.id/index.php/porosonim>
32. AZIMAH RN, KHASANAH IN, PRATAMA R, AZIZAH Z, FEBRIANTORO W, PURNOMO SRS. ANALISIS DAMPAK COVID-19 TERHADAP SOSIAL EKONOMI PEDAGANG DI PASAR KLATEN DAN WONOGIRI. *EMPATI: Jurnal Ilmu Kesejahteraan Sosial*. 2020 Sep 29;9(1):59–68.
33. Aeni N, Perencanaan B, Daerah P, Pati K, Raya J, Km PK, et al. Pandemi COVID-19: Dampak Kesehatan, Ekonomi, dan Sosial COVID-19 Pandemic: The Health, Economic, and Social Effects [Internet]. Vol. 17. 2021. Available from: <http://>
34. Kesehatan Masyarakat F, Sulaiman L. Info Artikel:Diterima 25 Februari 2021; Disetujui 2 Mei 2021. Available from: <https://ejournal.undip.ac.id/index.php/mkmi>
35. Ilmiah Kesehatan Keperawatan J, Sabila Rosyad Y, Retno Wulandari S, Monika R, Febristi A, Mekar Sari D, et al. DAMPAK PANDEMI COVID-19 TERHADAP KESEHATAN MENTAL ORANG TUA DAN ANAK. 2021;17(1):42–7. Available from: <http://ejournal.stikesmuhgombong.ac.id>
36. Penelitian P, Keahlian B, Ri D, Nusantara G, Lt I, Subroto JGG, et al. KAJIAN SINGKAT TERHADAP ISU AKTUAL DAN STRATEGIS BIDANG HUBUNGAN INTERNASIONAL PUSLIT BKD PANDEMI COVID-19 SEBAGAI PERSOALAN SERIUS BANYAK NEGARA DI DUNIA.
37. Keperawatan J, Nugroho SA, Hidayat IN. Efektivitas Dan Keamanan Vaksin Covid-19 : Studi Refrensi.
38. Perbawa IKSLP. KEBIJAKAN PEMERINTAH INDONESIA DALAM MENANGGULANGI COVID-19 BERDASARKAN INSTRUMEN HUKUM INTERNASIONAL. *Jurnal Ilmu Sosial dan Humaniora*. 2021 Apr 10;10(1):197.
39. Artikel Fitriyana.

40. R DL, M AS, H AA. Edukasi Mengenai Herd Immunity Dan Vaksinasi COVID-19 Kepada Tenaga Kefarmasian di Indonesia [Internet]. Vol. 3, Juli-Desember. Available from: <http://journal.uta45jakarta.ac.id/index.php/berdikari/index>
41. 70-Article Text-341-1-10-20200622 (3).
42. Supriyadi S. The future of vaccination and herd immunity in the COVID-19 pandemic. MEDISAINS. 2021 Sep 6;19(2):25.
43. 1\_Basic\_Concept\_of\_Vaccination.
44. Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Vol. 21, Nature Reviews Immunology. Nature Research; 2021. p. 83–100.
45. Krammer F. SARS-CoV-2 vaccines in development. Vol. 586, Nature. Nature Research; 2020. p. 516–27.
46. Han X, Xu P, Ye Q. Analysis of COVID-19 vaccines: Types, thoughts, and application. Vol. 35, Journal of Clinical Laboratory Analysis. John Wiley and Sons Inc; 2021.
47. Kesehatan PharmaMedika M, Panjiasih Susmiarsih T. Kajian DNA Rekombinan pada Vaksin DNA dan Vaksin Subunit Protein Study of Recombinant DNA in DNA Vaccines and Protein Subunit Vaccines. Vaksin Subunit Protein..... 108(2).
48. Vaccine components [Internet]. Available from: [http://www.ncirs.edu.au/assets/provider\\_resources/fact-](http://www.ncirs.edu.au/assets/provider_resources/fact-)
49. MODULE 2 – Components of a vaccine - WHO Vaccine Safety Basics.
50. Sharma O, Sultan AA, Ding H, Triggler CR. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Vol. 11, Frontiers in Immunology. Frontiers Media S.A.; 2020.
51. Zahid MN, Moosa MS, Perna S, Buti E bin. A review on COVID-19 vaccines: stages of clinical trials, mode of actions and efficacy. Vol. 28, Arab Journal of Basic and Applied Sciences. Taylor and Francis Ltd.; 2021. p. 225–33.
52. Nikhra V. Chronic GI Disorders View project Diabetes and Aging View project Stages in COVID-19 vaccine development: The Nemesis, the Hubris and the Elpis More Information. 2020; Available from: <https://www.heighpubs.org/hjcv>
53. Singh K, Mehta S. The clinical development process for a novel preventive vaccine: An overview. Vol. 62, Journal of Postgraduate Medicine. Medknow Publications; 2016. p. 4–11.
54. 1\_Basic\_Concept\_of\_Vaccination.
55. VACCINE SAFETY BASICS Learning manual. 2013.
56. Zahid MN, Moosa MS, Perna S, Buti E bin. A review on COVID-19 vaccines: stages of clinical trials, mode of actions and efficacy. Vol. 28, Arab Journal of Basic and Applied Sciences. Taylor and Francis Ltd.; 2021. p. 225–33.

57. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. *Nature*. 2020 Oct 22;586(7830):589–93.
58. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New England Journal of Medicine*. 2020 Dec 31;383(27):2603–15.
59. Nihra V. Chronic GI Disorders View project Diabetes and Aging View project Stages in COVID-19 vaccine development: The Nemesis, the Hubris and the Elpis More Information. 2020; Available from: <https://www.heighpubs.org/hjcv>
60. Anderson EJ, Roupael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. *New England Journal of Medicine*. 2020 Dec 17;383(25):2427–38.
61. Keperawatan J, Nugroho SA, Hidayat IN. Efektivitas Dan Keamanan Vaksin Covid-19 : Studi Refrensi.
62. Palacios R, Patiño EG, de Oliveira Piorelli R, Conde MTRP, Batista AP, Zeng G, et al. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac – PROFISCOV: A structured summary of a . *Trials*. 2020;21(1):21–3.
63. Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. *New England Journal of Medicine*. 2020;383(24):2320–32.
64. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *The Lancet*. 2021;397(10269):99–111.
65. Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. *New England Journal of Medicine*. 2020;383(25):2439–50.
66. Baden LR, el Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *New England Journal of Medicine*. 2021;384(5):403–16.